Targeting Ovarian Cancer with Chalcone Derivatives: Cytotoxicity and Apoptosis Induction in HGSOC Cells.
Elif Merve Aydınİdil Su CanıtezEleonora ColomboSalvatore PrinciottoDaniele PassarellaSabrina DallavalleMichael S ChristodoulouIrem Durmaz SahinPublished in: Molecules (Basel, Switzerland) (2023)
Ovarian cancer ranks as the eighth most prevalent form of cancer in women across the globe and stands as the third most frequent gynecological cancer, following cervical and endometrial cancers. Given its resistance to standard chemotherapy and high recurrence rates, there is an urgent imperative to discover novel compounds with potential as chemotherapeutic agents for treating ovarian cancer. Chalcones exhibit a wide array of biological properties, with a particular focus on their anti-cancer activities. In this research, we documented the synthesis and in vitro study of a small library of chalcone derivatives designed for use against high-grade serous ovarian cancer (HGSOC) cell lines, specifically OVCAR-3, OVSAHO, and KURAMOCHI. Our findings revealed that three of these compounds exhibited cytotoxic and anti-proliferative effects against all the tested HGSOC cell lines, achieving IC 50 concentrations lower than 25 µM. Further investigations disclosed that these chalcones prompted an increase in the subG1 phase cell cycle and induced apoptosis in OVCAR-3 cells. In summary, our study underscores the potential of chalcones as promising agents for the treatment of ovarian cancer.
Keyphrases
- induced apoptosis
- endoplasmic reticulum stress
- high grade
- oxidative stress
- cell cycle
- cell cycle arrest
- signaling pathway
- papillary thyroid
- cell proliferation
- cell death
- low grade
- squamous cell
- type diabetes
- metabolic syndrome
- pregnant women
- polycystic ovary syndrome
- childhood cancer
- human health
- radiation therapy
- drug delivery
- high throughput
- insulin resistance
- endometrial cancer
- locally advanced
- anti inflammatory
- combination therapy